The average TYME TECHNOLOGIES stock price prediction forecasts a potential upside of from the current TYME share price of 027. Real-time trade and investing ideas on Tyme Technologies Inc TYME from the largest community of traders and investors. Youll find the Tyme Technologies share forecasts stock quote and buy sell signals belowAccording to present data Tyme Technologiess RFL shares and potentially its market environment have been in bearish. 2 hours agoCitigroup downgraded shares of iRhythm Technologies from a buy rating to a neutral rating and cut their price target for the stock from 18000 to 15500 in a report on Thursday June 9th. Tyme Technologies Incs upside potential average analyst target price relative to current price is higher than 9832 of all US stocks. The successful prediction of Tyme Technologies future price could yield a significant profit. The future direction and impact of these initiatives is unknown.& & Being a public company is expensive and administratively burdensome.Pin On Cheer The average price target is 95 which means analysts expect the stock to rise by 60370 over the next twelve months. Any of these outcomes could have a material adverse effect on our business. In addition, we may not pursue or obtain patent protection in all relevant markets. TYME remains responsible for the remaining promotional effort. We expect to continue to incur losses for the near future. 8226 A shortage of drug product and/or the agents used with our drug candidates. We may not be successful in any step in such a transition. 8226 Our business may experience a material economic effect. We do not anticipate paying dividends on our common stock. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA subjects drug products to extensive pre- and post-market regulation. As a result, they may provide significant, additional competition for SM-88. There are a variety of available drug therapies marketed for cancer. We also rely on trademark laws to protect our proprietary rights. No adverse events resulted in dose delay, discontinuation, or reduction.
Need to identify clear development pathway for TYME-19. & Therefore, the Company launched a SM-88 biomarker initiative. Breast cancer is a priority indication for development. Our lead first-in-class CMBT compound is SM-88 (racemetryrosine). All information and data on this website cannot be guaranteedĪccuracy, completeness and appropriateness - neither explicit nor implicit. This website is for information purposes only. We cannot guarantee the success of any investment you make based on the information published here. With the help of past performance, such developments are subject to a multitude of different influences. Our mathematical models are a tool to try to explore the possibility for future price development Or the tax implications an investment may have for the investor. Experience and risk profile of an individual investor Our forecasts cannot reflect the specific situation.
Investments require additional considerations. That may be relevant for future security price flows. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or We do not investigate the issuers of the securities to which our forecasts relate, nor do we considerĪny financial data or other data of such issuers with the exception of the past prices of the securities. If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and Information about these prices is provided to us by third parties.
Which are exclusively based on the prices of these securities in the past. The website offers price forecasts and analysis tools for equities and other securities, Our forecast model is based on mathematical, statistical methods. The forecast (dashed curve) of the share price performance is based on historical data. The information can be used for day trading.
Tyme stock forecast 2025 download#
You can export / download forecasted data as CSV file, no login required. On our site we made daily predictions for finance products based on statistical analysis.
0 kommentar(er)
